Susanna High Biography and Net Worth

COO of Dyne Therapeutics

Susanna has more than two decades of experience leading corporate strategy, portfolio management, business planning and operations for biotechnology companies. In her most recent position, she served as chief operating officer of bluebird bio where her numerous responsibilities included the advancement of the company’s severe genetic disease portfolio, leading to the European filing and then approval of ZYNTEGLO®, a gene therapy for the treatment of transfusion-dependent beta-thalassemia, as well as overseeing the build-out of its European organization. Before joining bluebird, Susanna worked in roles of increasing responsibility at Alnylam Pharmaceuticals, including as senior vice president, strategy and business integration, where she led corporate and portfolio strategy, program and alliance management, business planning and information technology. Previously, she supported corporate strategy and business operations at Millennium Pharmaceuticals (now Takeda Oncology). Susanna holds an M.S. in economics and business management from Bocconi University in Italy and an M.B.A. from the MIT Sloan School of Management.

What is Susanna High's net worth?: The estimated net worth of Susanna High is at least $3.91 million as of September 18th, 2024. Ms. High owns 131,636 shares of Dyne Therapeutics stock worth more than $3,908,273 as of November 23rd. This net worth estimate does not reflect any other assets that Ms. High may own. Additionally, Ms. High receives a salary of $754,100.00 as COO at Dyne Therapeutics. Learn More about Susanna High's net worth.
How old is Susanna High?: Ms. High is currently 56 years old. There are 7 older executives and no younger executives at Dyne Therapeutics. Learn More on Susanna High's age.
What is Susanna High's salary?: As the COO of Dyne Therapeutics, Inc., Ms. High earns $754,100.00 per year. Learn More on Susanna High's salary.
How do I contact Susanna High?: The corporate mailing address for Ms. High and other Dyne Therapeutics executives is 1560 Trapelo Road, Waltham, MA 02451, United States. Dyne Therapeutics can also be reached via phone at 781-786-8230 and via email at [email protected]. Learn More on Susanna High's contact information.
Has Susanna High been buying or selling shares of Dyne Therapeutics?: Susanna High has not been actively trading shares of Dyne Therapeutics within the last three months. Most recently, Susanna Gatti High sold 8,976 shares of the business's stock in a transaction on Wednesday, September 18th. The shares were sold at an average price of $34.41, for a transaction totalling $308,864.16. Following the completion of the sale, the chief operating officer now directly owns 131,636 shares of the company's stock, valued at $4,529,594.76. Learn More on Susanna High's trading history.
Who are Dyne Therapeutics' active insiders?: Dyne Therapeutics' insider roster includes Oxana Beskrovnaya (Chief Scientific Officer), Joshua Brumm (CEO), John Cox (President & CEO), Wildon Farwell (Insider), Susanna High (COO), Dirk Kersten (Director), and Richard Scalzo (Insider). Learn More on Dyne Therapeutics' active insiders.
Are insiders buying or selling shares of Dyne Therapeutics?: During the last year, Dyne Therapeutics insiders bought shares 2 times. They purchased a total of 1,746,285 shares worth more than $31,057,267.50. During the last year, insiders at the sold shares 51 times. They sold a total of 2,551,709 shares worth more than $62,622,812.31. The most recent insider tranaction occured on November, 18th when Director Carlo Incerti sold 16,500 shares worth more than $474,045.00. Insiders at Dyne Therapeutics own 20.8% of the company. Learn More about insider trades at Dyne Therapeutics.
Information on this page was last updated on 11/18/2024.

Susanna High Insider Trading History at Dyne Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/18/2024	Sell	8,976	$34.41	$308,864.16	131,636
6/24/2024	Sell	10,163	$35.33	$359,058.79	148,792
6/21/2024	Sell	29,787	$35.01	$1,042,842.87	148,792
6/12/2024	Sell	40,000	$33.36	$1,334,400.00	148,792
6/10/2024	Sell	80,000	$30.24	$2,419,200.00	154,062
5/16/2024	Sell	2,738	$28.27	$77,403.26	154,062
3/11/2024	Sell	2,292	$25.70	$58,904.40	156,800
3/7/2024	Sell	1,591	$25.85	$41,127.35	186,291
12/11/2023	Sell	1,616	$10.72	$17,323.52	187,882
11/2/2023	Sell	9,939	$7.40	$73,548.60	94,605
9/18/2023	Sell	2,672	$9.41	$25,143.52	104,544
9/12/2023	Sell	1,635	$10.41	$17,020.35	107,216
6/13/2023	Sell	1,625	$12.43	$20,198.75	108,851
3/14/2023	Sell	1,559	$13.33	$20,781.47	110,476
12/12/2022	Sell	751	$10.87	$8,163.37	112,035
3/11/2022	Sell	765	$8.73	$6,678.45
9/23/2021	Sell	2,451	$17.22	$42,206.22

Susanna High Buying and Selling Activity at Dyne Therapeutics

Dyne Therapeutics Company Overview

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $29.69

$29.18

$30.37

50 Day Range

MA: $32.16

$28.13

$36.59

2 Week Range

Now: $29.69

$10.12

$47.45

Volume

851,011 shs

Average Volume

1,484,052 shs

Market Capitalization

$3.02 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.1

Election warning coming true…

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - watch it before it's too late.

Click here to watch it now.

Susanna High Biography and Net Worth

What is Susanna High's net worth?

How old is Susanna High?

What is Susanna High's salary?

How do I contact Susanna High?

Has Susanna High been buying or selling shares of Dyne Therapeutics?

Who are Dyne Therapeutics' active insiders?

Are insiders buying or selling shares of Dyne Therapeutics?